Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale

Charles Ryan, Amy M. Lin, Eric J. Small

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.

Original languageEnglish (US)
Pages (from-to)250-253
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number3
DOIs
StatePublished - May 1 2006
Externally publishedYes

Keywords

  • Angiogenesis inhibitors
  • Bevacizumab
  • Hormone refractory prostate cancer
  • Prostate cancer

Fingerprint Dive into the research topics of 'Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale'. Together they form a unique fingerprint.

Cite this